Clinical Trials In Columbus
Discover hundreds of clinical trials in Columbus.
Search clinical trials in Columbus by condition or phase.
Academic-Community EPINET (AC-EPINET)
Sponsor:
Indiana University
Location:
Code:
NCT04497857
Conditions
Schizophrenia
Schizoaffective Disorder
Schizophreniform Disorders
Major Depression with Psychotic Features
Bipolar Disorder with Psychotic Features
Eligibility Criteria
Sex: All
Age: 16 - 35
Healthy Volunteers: Not accepted
Interventions
Coordinated Specialty Care (CSC)
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
Sponsor:
Janssen Research & Development, LLC
Location:
Code:
NCT05754957
Conditions
Acute Coronary Syndrome
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Milvexian
Placebo
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
Sponsor:
Margaret Gatti-Mays
Location:
Code:
NCT06026657
Conditions
Anatomic Stage IV Breast Cancer AJCC v8
HER2-Negative Breast Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Computed Tomography
Gemcitabine
Magnetic Resonance Imaging
Naxitamab
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT03871257
Conditions
Low Grade Glioma
Neurofibromatosis Type 1
Visual Pathway Glioma
Eligibility Criteria
Sex: All
Age: 2 - 21
Healthy Volunteers: Not accepted
Interventions
Carboplatin
Magnetic Resonance Imaging
Quality-of-Life Assessment
Questionnaire Administration
Selumetinib Sulfate
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
Sponsor:
Novartis Pharmaceuticals
Location:
Code:
NCT04174157
Conditions
Spinal Muscular Atrophy (SMA)
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
Prospective observational registry
Zolgensma
A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma
Sponsor:
GlaxoSmithKline
Location:
Code:
NCT06261957
Conditions
Asthma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Salbutamol HFA-134a
Salbutamol HFA-152a
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
Sponsor:
Douglas Scharre
Location:
Code:
NCT03019757
Conditions
Alzheimer's Disease
Lewy Body Dementia
Parkinson's Disease
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
DaTscan
F18-AV-45
FDG-PET
APOE genotype
Polysomnogram
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
Sponsor:
SURGE Therapeutics
Location:
Code:
NCT05710848
Conditions
Non-muscle-invasive Bladder Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
STM-416
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Sponsor:
Sutro Biopharma, Inc.
Location:
Code:
NCT05870748
Conditions
Ovarian Cancer
Epithelial Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer
Platinum-resistant Ovarian Cancer
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Luveltamab tazevibulin
Pegfilgrastim
Gemcitabine
Paclitaxel
Pegylated liposomal doxorubicin
A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration
Sponsor:
Pediatric Brain Tumor Consortium
Location:
Code:
NCT04201457
Conditions
Low Grade Glioma (LGG) of Brain With BRAF Aberration
High Grade Glioma (HGG) of the Brain With BRAF Aberration
Low Grade Glioma of Brain With Neurofibromatosis Type 1
Eligibility Criteria
Sex: All
Age: 1 - 30
Healthy Volunteers: Not accepted
Interventions
Dabrafenib
Trametinib
Hydroxychloroquine